At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

Aziyo Biologics (AZYO) intends to raise $50 million in an IPO of its Class A common stock, according to an S-1 registration statement. Silver Spring, Maryland-based Aziyo was founded to develop a ...

From its inception in 2015, the company has been focused exclusively on discovering and developing innovative biologics, including monoclonal antibodies (mAbs), fusion proteins and bispecific ...

Public health has come a long way over the past 70 years, and so has KM Biologics and its predecessor, Kaketsuken. From their involvement in the smallpox eradication efforts in the 1940s and 1950s ...

Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative ...

Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate response or intolerable adverse events. Evidence from observational studies and ...

That's mostly due to two types of prescriptions, disease-modifying antirheumatic drugs or DMARDs and biologics. Conventional DMARDs including pills like methotrexate and hydroxychloroquine ...

Designed to treat autoimmune disorders, biologics are unique. Drugs genetically engineered inside living cells. If you have an autoimmune disease, your immune system is attacking your own healthy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The most recent trading session ended with Adma Biologics (ADMA) standing at $20.33, reflecting a -1.91% shift from the previouse trading day's closing. The stock trailed the S&P 500, which ...